Alexander Yur'Evich Mayorov

A deformeter is a deflection device that measures such structural and mechanical properties of cheese as hardness and elasticity. This technology facilitates cheese quality control. The article describes its operation principles and application options in cheese production. A penetrometer is the most common device for assessing the hardness of cheese. However, it cannot measure plasticity. A deformeter, on the other hand, tests both the elastic and plastic properties of cheese. This research featured Reokon 240 deflection device developed at the Siberian Research Institute of Cheese Making. Hardness was expressed as the maximal value of the force applied to the indenter under compression while elasticity was the reduction magnitude on the indenter. The indenter moved at a constant speed, compressing the cheese sample from the original size of 10 mm to that of 6.4 mm. Fixed in this position, the force on the indenter decreased as the stress in the compressed cheese sample relaxed. The test results were compared with those obtained by traditional methods. The experimental hardness data registered with Reokon 240 correlated well with the those obtained by the classical penetration method. The minimal relaxation coefficient belonged to the sample of Parmesan cheese, which had the greatest hardness and was less prone to stress relaxation. The highest relaxation coefficient belonged to the Feta cheese sample, which appeared to be more plastic. These data correlated well with the mass fraction of moisture in the cheese samples. Reokon 240 proved to be an objective instrument of cheese texture assessment. In addition, it could also measure cheese plasticity during pressing. The scope of application could be extended to the rheological properties of fruits and berries.

This article discusses the encapsulation of biologically active additives (BAA) and probiotics by spraying method. Today, a large number of BAA are registered in the country, the issue of rational classification of BAA is relevant. In the production of BAA, the use of plants, fungi and BAA that pose a danger to human life and health is not allowed. Currently, the importance of probiotics for enhancing and maintaining human immunity is emphasized.There are many technologies for encapsulating dietary supplements and probiotics: extrusion, spray drying, spray freezing, addition to the matrix, gel encapsulation, encapsulation in a fluidized bed. Based on the literature review, alginate polymer encapsulation technologies are considered.Sodium alginate was selected as the materials for the experiments. A solution of sodium alginate has been prepared. Capsules obtained from 0.5% sodium alginate are soft, with an inhomogeneous surface, not spherical in shape, which is due to the low viscosity of sodium alginate, the average size was 2,0×10^-3м.In an experiment with a concentration of a solution of 1% sodium alginate, it was not possible to obtain capsules by spraying due to the high viscosity. The capsules were obtained by the drip method, had a rounded shape, dense structure, the average size was 3,2×10^-3м.

Introduction. Insulin therapy is the only treatment for type 1 DM and one of the options for intensifying the treatment for type 2 DM. The production of own insulin biosimilars will increase patients access to the providing drugs and can potentially reduce medical costs on healthcare for government. Aim. Compare the equivalence of pharmacokinetics (PK) and pharmacodynamics (PD), safety, efficacy, and immunogenicity between insulin biosimilar RinLis®, 100 IU/ml (LLC GEROPHARM, Russia) to original Humalog®, 100 IU/ml (Lilly France, France). Materials and methods. The clinical trial was conducted in two phases. Phase I – randomized double-blind, two-arm crossover study of PK and PD using hyperinsulinemic euglycemic clamp (HEC) method in 28 healthy volunteers (NCT03604575). During HEC regular blood sampling was performed to assess glucose and insulin concentrations. The glucose infusion rate (GIR) was adjusted based on glycemia measurement. These data were used to calculate the PD parameters: the total area under the GIR-time curve (AUC_GIR) and the maximum GIR over the observation period (GIR_max); PK parameters: the total area under the concentration – time curve (AUC_ins.) and the maximum insulin concentration over the HEC (С_{ins. max}). Phase II – randomized multicenter open-label comparative study in parallel groups with an assessment the frequency of an immune response after 26 weeks of therapy (NCT04023344). The comparability of the studied drugs was considered proven if 90% confidence intervals (CI) for the ratio of geometric means of FC and PD were in the range of 80–125%. Results. In the course of the study, it was revealed that RinLiz® and Humalog® insulin had comparable PK and PD profiles. The ratio of the geometric mean values of the AUC_GIR and GIR_max were in the range of 80–125% and amounted to 106 [95–118] % and 108 [97–121] %, respectively. The equivalence also was confirmed by the ratio of the geometric mean values of the AUC_ins. and С_{ins. max}, which amounted to 91 [86–97] % and 94 [91–97] %. In the second phase of the study after 26 weeks of therapy the frequency of immune response between two groups did not differ. Conclusion. The obtained data have demonstrated the bioequivalence and immunogenicity of RinLiz® insulin to the original Humalog® in terms of PK, PD and safety parameters.

Background: Components of metabolic syndrome can be observed in patients with primary hyperparathyroidism (PHPT). The link between these disorders remains unclear due to the lack of relevant experimental models and the heterogeneity of examined groups. The effect of surgery on metabolic abnormalities is also controversial. We conducted a comprehensive assessment of metabolic parameters in young patients with PHPT. Methods: One-center prospective comparative study was carried out. The participants underwent a complex biochemical and hormonal examination, a hyperinsulinemic euglycemic and hyperglycemic clamps, a bioelectrical impedance analysis of the body composition before and 13 months after parathyroidectomy compared to sex-, age- and body mass index matched healthy volunteers. Results: 45.8% of patients (n = 24) had excessive visceral fat. Insulin resistance was detected in 54.2% of cases. PHPT patients had higher serum triglycerides, lower M-value and higher C-peptide and insulin levels in both phases of insulin secretion compared to the control group (p < 0.05 for all parameters). There were tendencies to decreased fasting glucose (p = 0.031), uric acid (p = 0.044) and insulin levels of the second secretion phase (p = 0.039) after surgery, but no statistically significant changes of lipid profile and M-value as well as body composition were revealed. We obtained negative correlations between percent body fat and osteocalcin and magnesium levels in patients before surgery. Conclusion: PHPT is associated with insulin resistance that is the main risk factor of serious metabolic disorders. Surgery may potentially improve carbohydrate and purine metabolism.

BACKGROUND: Despite progress in the treatment of patients with diabetes mellitus (DM), the problem of achieving target values of glycemic control remains relevant. In this regard, the search for new integrated solutions that could strengthen disease control and improve clinical outcomes becomes relevant.AIM: To assess the impact of the developed integrated approach to disease management on the clinical and metabolic outcomes of patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) participating in the “NORMA” pilot program for 3 and 6 months.MATERIALS AND METHODS: “NORMA” is the first Russian program designed to implement an integrated approach to DM management combines structured online education, blood glucose monitoring, supervision by endocrinologist, and administrative support. Interium retrospective analysis analysis of pre-existing data generated in the Program was performed from October 2020 to November 2021. Adults (≥18 years) with uncontrolled T1DM or T2DM on insulin (HbA_1c>7,0%) with duration of DM ≥6 months were included. The following characteristics were considered: social-demographic parameters, duration of DM, complications, HbA_1c, hypoglycemia events, daily insulin dose, patients’ perception of DM checklist (scaled 1-10), level of DM knowledge (questionnaire of 20 points).RESULTS: Data from 185 persons were analyzed: 132 with T1DM and 53 with T2DM, 67% women, the mean age was 41.3±14.4 years; the median DM duration was 12.0 [6.0; 19.0] years, 30 persons (16.3%) were free of any DM complications. Mean HbA_1c decreased from 8.8±1.5% to 7.4±1.2% at month 3, and to 7.6±1.5% at month 6 (p1c CONCLUSION: In a real-life setting, the implementation of an integrated approach to the diabetes management was associated with the improvement of glycemic control without significant changes of total insulin dose.

The manual for healthcare professionals and nurses to be used for the education of type 1 diabetes mellitus patients was developed by the employees of Endocrinology Research Centre in accordance with clinical guidelines, WHO and IDF recommendations and is based on the principle of structuring patient education. The manual contains a plan of classes and topics necessary for patients. The content of the classes is presented in a language understandable to the patients. Specific medical terminology is not used. Education of patients using the proposed program can be carried out both in the in-patients hospital and on an outpatient basis, depending on the conditions available in a particular medical institution. Approved and recommended for use by the Russian Association of Endocrinologists.

The manual for healthcare professionals and nurses to be used for the education of type 2 diabetes mellitus patients receiving insulin therapy was developed by the employees of Endocrinology Research Centre in accordance with clinical guidelines, WHO recommendations and is based on the principle of structuring patient education. The manual contains a plan of classes and topics necessary for patients. The content of the classes is presented in a language understandable to the patients. Specific medical terminology is not used. Education of patients using the proposed program can be carried out both in the in-patients hospital and on an outpatient basis, depending on the conditions available in a particular medical institution. Approved and recommended for use by the Russian Association of Endocrinologists.

The manual for healthcare professionals and nurses to be used for the education of type 2 diabetes mellitus patients receiving insulin therapy was developed by the employees of Endocrinology Research Centre in accordance with clinical guidelines, WHO recommendations and is based on the principle of structuring patient education. The manual contains a plan of classes and topics necessary for patients. The content of the classes is presented in a language understandable to the patients. Specific medical terminology is not used. Education of patients using the proposed program can be carried out both in the in-patients hospital and on an outpatient basis, depending on the conditions available in a particular medical institution. Approved and recommended for use by the Russian Association of Endocrinologists.

The manual for healthcare professionals and nurses to be used for the education of type 1 diabetes mellitus patients receiving insulin pump therapy and continuous glucose monitoring was developed by the employees of Endocrinology Research Centre in accordance with clinical guidelines, WHO and IDF recommendations and is based on the principle of structuring patient education. The manual contains a plan of classes and topics necessary for patients. The content of the classes is presented in a language understandable to the patients. Specific medical terminology is not used. Education of patients using the proposed program can be carried out both in the in-patients hospital and on an outpatient basis, depending on the conditions available in a particular medical institution. Approved and recommended for use by the Russian Association of Endocrinologists.

Aim:present clinical guidelines, aimed at general practitioners, gastroenterologists, cardiologists, endocrinologists, comprise up-to-date methods of diagnosis and treatment of non-alcoholic fatty liver disease.Key points.Nonalcoholic fatty liver disease, the most wide-spread chronic liver disease, is characterized by accumulation of fat by more than 5 % of hepatocytes and presented by two histological forms: steatosis and nonalcoholic steatohepatitis. Clinical guidelines provide current views on pathogenesis of nonalcoholic fatty liver disease as a multisystem disease, methods of invasive and noninvasive diagnosis of steatosis and liver fibrosis, principles of nondrug treatment and pharmacotherapy of nonalcoholic fatty liver disease and associated conditions. Complications of nonalcoholic fatty liver disease include aggravation of cardiometabolic risks, development of hepatocellular cancer, progression of liver fibrosis to cirrhotic stage.Conclusion.Progression of liver disease can be avoided, cardiometabolic risks can be reduced and patients' prognosis — improved by the timely recognition of diagnosis of nonalcoholic fatty liver disease and associated comorbidities and competent multidisciplinary management of these patients.